(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

In breast cancer, the primary site residual burden of disease (PRBD) after neoadjuvant chemotherapy has been shown to correlate with poor prognostic outcomes. Currently, there is no established standard of care to offer patients with residual disease, in terms of adjuvant systemic treatment after full-dose neoadjuvant chemotherapy.

Parima Daroui, MD, PhD, Saud Siddiqui, BA, Nilam Ramsinghani, MD, Rita Mehta, MD, Lydia Su, PhD; University of California, Irvine

Introduction: In breast cancer, the primary site residual burden of disease (PRBD) after neoadjuvant chemotherapy has been shown to correlate with poor prognostic outcomes. Currently, there is no established standard of care to offer patients with residual disease, in terms of adjuvant systemic treatment after full-dose neoadjuvant chemotherapy.

Materials and Methods: We retrospectively analyzed data from patients treated on an institutional review board (IRB)-approved institutional protocol of neoadjuvant chemotherapy followed by surgery to determine whether patients with intermediate- or high-grade breast cancer, with T2 disease or greater, and with a PRDB greater than 0.5 cm demonstrate worse outcomes without further adjuvant systemic treatment.

Results: The review included 11 patients with breast cancer treated between 2007–2011 with neoadjuvant chemotherapy followed by mastectomy or lumpectomy and followed by adjuvant radiation treatment (RT). A total of five patients with PRBD greater than 0.5 mm received an additional 3–4 cycles of anthracycline-based chemotherapy after surgery, followed by RT. Six patients with PRBD greater than 0.5 mm had radiation alone after surgery with no additional chemotherapy. Four of the five patients receiving additional systemic treatment for PRBD and all patients treated with RT alone had triple-negative or human epidermal growth factor receptor 2 (HER2)-positive status. On preliminary analysis in a median follow-up of 31 months (range: 18–47 mo) for patients receiving chemotherapy and a median follow-up of 45 months (range: 18–68 mo) for patients receiving RT alone, there was no evidence of disease recurrence (local or distant), based on imaging or clinical examination in any of the 11 patients.

Conclusions: Although limited, these preliminary data may provide a basis for future studies to correlate disease outcomes and pathological data, including initial nodal disease burden and pathological response to treatment.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content